Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
26 Results for "
dry eye disease
" in MedChemExpress (MCE) Product Catalog:
Products (26)
26 Results for "dry eye disease" in MCE Product Catalog:
12
Target:
Research Areas:
Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
12
12 Publications Verification
Cat. No.: HY-19344A
CAS No.: 1119276-80-0
Synonyms: SAR 1118 sodium; SHP-606 sodium
Target:
Research Areas:
Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease .
5
Target:
Research Areas:
Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.
Cat. No.: HY-172435
CAS No.: 1431754-15-2
Synonyms: AGN-232411; AG-80308; AGN-411
Target:
Research Areas:
Rezuforimod (AGN-232411; AG-80308) is an ophthalmic solution targeting the formyl peptide receptor (FPR) pathway. Rezuforimod exerts anti-inflammatory effects by targeting the formyl peptide receptor pathway. Administered topically, Rezuforimod significantly reduces the corneal conjunctival staining score and improves ocular discomfort symptoms, with no serious adverse events reported and favorable overall safety profile. Rezuforimod shows remarkable potential to serve as a novel therapeutic option for dry eye disease .
Synonyms: SYL1001 sodium
Research Areas:
Tivanisiran sodium (SYL1001 sodium) is a small interfering RNA (siRNA) targeting TRPV1 . Tivanisiran sodium induces the degradation of TRPV1 mRNA, thereby inhibiting protein synthesis. Tivanisiran sodium alleviates ocular discomfort and pain, and improves ocular hyperemia and tear quality. Tivanisiran sodium is applicable to research related to dry eye disease .
Synonyms: DA-6034 free acid
Target:
Research Areas:
Recoflavone (DA-6034 (free acid)), a synthetic derivative of the flavonoid Eupatilin (HY-N0783), is orally active. Recoflavone can inhibit the NF-κB pathway and induce [Ca( 2+)]i increase in epithelial cells. Recoflavone exhibits activities such as anti-inflammation, anti-tumor effects, protection of gastric and intestinal mucosa, and promotion of secretion in the ocular surface and salivary glands. Recoflavone can be used for the research of diseases such as dry eye, gastric injury, and intestinal injury .
Cat. No.: HY-W143531
CAS No.: 133331-77-8
Synonyms: NOV03; SHR8058
Target:
Research Areas:
Perfluorohexyloctane (NOV03), a semifluorinated alkane, reduces tear film instability in Meibomian gland dysfunction and evaporative dry eye disease. Perfluorohexyloctane is a long-term tamponade agent. Perfluorohexyloctane increases tear film breakup time and lipid layer thickness .
Target:
Research Areas:
CFTR activator 1 is a potent and selective CFTR activator, with an EC50 of 23 nM. CFTR activator 1 can be used to ameliorate dry eye disease .
Cat. No.: HY-P10904
CAS No.: 51486-77-2
Synonyms: ST-100
Synonyms: SYL1001
Research Areas:
Tivanisiran (SYL1001) is a small interfering RNA (siRNA) targeting TRPV1 . Tivanisiran induces the degradation of TRPV1 mRNA, thereby inhibiting protein synthesis. Tivanisiran alleviates ocular discomfort and pain, and improves ocular hyperemia and tear quality. Tivanisiran is applicable to research related to dry eye disease .
Target:
P2Y Receptor G-quadruplex Phospholipase PKC Src CaMK PI3K Akt NO Synthase PERK Sodium Channel
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
MRS2768 tetrasodium salt is a potent, selective, and metabolically stable P2Y2 receptor agonist with an EC50 of 1.89 μM for the human P2Y2 receptor. MRS2768 tetrasodium salt activates Gq/PLC/PKC signaling, leading to downstream phosphorylation of Akt, eNOS, and ERK, with effects varying by cell type. MRS2768 tetrasodium salt inhibits ENaC via Gq/PKC/Src/Akt to promote natriuresis and lower blood pressure in the kidney. MRS2768 tetrasodium salt activates eNOS to increase NO secretion in endothelial cells. MRS2768 tetrasodium salt drives proliferation via PI3K/Akt in fibroblasts and cancer cells. MRS2768 tetrasodium salt exerts anti-apoptotic effects through PKC/Src/Akt in cardiomyocytes. MRS2768 tetrasodium salt can be applied to investigate P2Y2-dependent pathological processes, including acute kidney injury, chronic kidney disease and renal fibrosis, DOCA-salt induced hypertension, myocardial infarction, pulmonary arterial hypertension, pancreatic cancer, cardiac fibrosis, dry eye disease, as well as shear stress-mediated vascular remodeling and atherosclerosis .
Cat. No.: HY-19344R
CAS No.: 1025967-78-5
Synonyms: SAR 1118 (Standard); SHP-606 (Standard)
Target:
Research Areas:
Lifitegrast (Standard) is the analytical standard of Lifitegrast. This product is intended for research and analytical applications. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease .
Cat. No.: HY-153565
CAS No.: 2316683-71-1
Target:
Research Areas:
Immune cell migration-IN-1 (compound 2) is a potent agent to inhibit immune cell migration. Immune cell migration-IN-1 can be used for research in alleviating dry eye diseases, eczema dermatitis and psoriasis .
Cat. No.: HY-117356A
CAS No.: 911391-37-2
MRS2693 ammonium is a selective P2Y6 receptor agonist. MRS2693 ammonium exerts biological effects by activating the Gq-coupled P2Y6 receptor, the ERK1/2 pathway, and the P2RY6-PLCB3-CAMKK2-PRKAA1-ULK1 signaling cascade. MRS2693 ammonium attenuates TNFα-induced NF-κB activation, stabilizes XIAP via AKT-mediated phosphorylation, induces autophagy, and reactivates PRKAA1. MRS2693 ammonium can be used in research on diseases including skeletal muscle ischemia/reperfusion injury, TNFα-induced skeletal muscle apoptosis, chronic myelomonocytic leukemia, colorectal cancer, and dry eye disease .
Cat. No.: HY-154994
CAS No.: 2891469-99-9
Target:
Research Areas:
JAK-IN-30 (compound 31) is a water-soluble JAK inhibitor with IC50 values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED) .
Cat. No.: HY-180939
Target:
Research Areas:
LFA-1-IN-2 (Compound 25) is a potent LFA-1 inhibitor with a Kd of 21.46 μM. LFA-1-IN-2 inhibits ICAM-1-mediated cell adhesion. LFA-1-IN-2 protects cells from inflammatory hyperosmotic stress. LFA-1-IN-2 improves dry eye disease .
Cat. No.: HY-19344S2
Cat. No.: HY-153567
CAS No.: 2260679-24-9
Target:
Research Areas:
Immune cell migration-IN-2 is a potent immune cell migration inhibitor with an EC50 of 13.5 nM in a T-cell adhesion assay. Immune cell migration-IN-2 is extracted from patent WO2019001171, example 11, can be used for dry-eye and other retinal diseases research . Immune cell migration-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-106449R
CAS No.: 203191-10-0
Synonyms: DA-6034 free acid (Standard)
Research Areas:
Recoflavone (Standard) is the analytical standard of Recoflavone (HY-106449). This product is intended for research and analytical applications. Recoflavone (DA-6034 (free acid)), a synthetic derivative of the flavonoid Eupatilin (HY-N0783), is orally active. Recoflavone can inhibit the NF-κB pathway and induce [Ca(2+)]i increase in epithelial cells. Recoflavone exhibits activities such as anti-inflammation, anti-tumor effects, protection of gastric and intestinal mucosa, and promotion of secretion in the ocular surface and salivary glands. Recoflavone can be used for the research of diseases such as dry eye, gastric injury, and intestinal injury .
Cat. No.: HY-171925
CAS No.: 752237-69-7
Target:
Research Areas:
BI-1124 is a cathepsin S inhibitor that exhibits simulated sufficient ocular pharmacokinetic-pharmacodynamic coverage in rabbit models via topical ocular administration. BI-1124 can be used for the research of age-related dry eye disease .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
